OX1R Inhibitors
3 drugsAbout OX1R
The orexin 1 receptor (OX1R) is a G protein-coupled receptor involved in regulating sleep-wake cycles and arousal. It is activated by the neuropeptides orexin A and orexin B, influencing neuronal activity and downstream signaling pathways.
OX1R has emerged as a significant pharmaceutical target, though currently there is no genetic evidence directly linking it to specific diseases. The clinical success of OX1R-modulating drugs underscores its therapeutic potential for sleep disorders.
Three FDA-approved drugs, DAYVIGO, QUVIVIQ, and BELSOMRA, target OX1R, all of which are small molecules. These drugs, developed by EISAI INC, IDORSIA, and Merck respectively, are approved for sleep disorders.
Top OX1R Drugs
Three companies, EISAI INC, IDORSIA, and Merck, have approved drugs targeting OX1R.
The limited number of players indicates a moderately concentrated market with potential entry barriers.
OX1R Drug Modality Landscape
Modalities
Routes of Administration
OX1R is amenable to small molecule drugs, with oral options available for convenient dosing.
The exclusive use of small molecules suggests an opportunity for alternative modalities like antibodies or peptides.
OX1R Clinical Trials 134 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on OX1R. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 32 | 29 | 0 | 3 | 100% |
| Phase 2 | 42 | 16 | 6 | 18 | 73% |
| Phase 3 | 18 | 14 | 0 | 4 | 100% |
| Phase 4 | 42 | 21 | 5 | 16 | 81% |
Top Sponsors
By Modality
Top Conditions
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved OX1R drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting OX1R. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
OX1R Drug Approval Timeline (2014 - 2022)
The first OX1R-targeting drug was approved in 2014, with the most recent approval in 2022.
The 9-year span between approvals suggests a potentially maturing market with slowing innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 67 (7 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on OX1R. A trial counts if an approved drug acting on OX1R is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.